2. Abstract
Background Ostial stenosis, a narrowing at the origin of coronary side branches, is commonly observed in branches diverging from stenotic coronary segments. However, it may also occur in branches diverging from non-stenotic segments, and the factors contributing to this phenomenon remain unclear.
Objectives This study aimed to assess the incidence of ostial stenosis in coronary side branches diverging from non-stenotic segments and to identify associated risk factors.
Methods We conducted a retrospective analysis of first-time, elective coronary angiograms (CAGs) from 884 patients. Side branches with a diameter larger than 2mm were included. Ostial stenosis was defined by two criteria: 1) the side branch diverged from a coronary segment with less than 25% diameter stenosis, and 2) the side branch exhibited ostial narrowing with more than 50% diameter stenosis. Clinical factors, including diabetes mellitus and lipid profiles, were assessed. Multivariate logistic regression was used to identify independent predictors of ostial stenosis.
Results Of the 4,739 side branches analyzed, 508 (10.7%) exhibited ostial stenosis. Ostial stenosis was present in 285 (32.2%) patients. Patients with ostial stenosis had a significantly higher prevalence of diabetes mellitus (60.0% vs. 33.0%, p<0.00001) and lower high-density lipoprotein (HDL) cholesterol levels (48.5 ± 14.6 mg/dL vs. 52.0 ± 14.9 mg/dL, p<0.01) compared to those without stenosis. No significant differences were found in other clinical factors. Multivariate analysis identified diabetes mellitus as an independent predictor of ostial stenosis (odds ratio: 0.29, 95% CI: 0.20-0.43, p<0.0001).
Conclusions Ostial stenosis in side branches diverging from non-stenotic coronary segments is significantly associated with diabetes mellitus. In diabetic patients, factors such as negative arterial remodeling, insulin resistance, and endothelial dysfunction likely play key roles in the development of this condition. These findings suggest that ostial stenosis could be an additional marker of advanced coronary artery disease in diabetes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors declare that no external funding was received for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Suwa Central Hospital gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data supporting the findings of this study are included within the manuscript.
Abbreviations
- CAG
- coronary angiogram
- PCI
- percutaneous coronary intervention
- HDL
- high-density lipoprotein
- CAD
- coronary artery disease
